Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05185024
Other study ID # PhL-2021-IRON-RELOAD
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date January 19, 2022
Est. completion date January 10, 2024

Study information

Verified date November 2023
Source PharmaLinea Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is designed as a parallel, randomized, double blind, three-arm single-center study exploring the efficacy and safety of 12-week once daily oral dosing of iron for correction of overall iron status in 150 otherwise healthy iron-deficient adults presenting with or without mild microcytic anemia. Three iron-containing preparations in the form of either Ferrous Sulfate Capsules, >Your< Iron Forte Capsules, or >Your< Iron Forte Liquid will be tested. Potential study participants will be recruited from the general population of 18-50 year old adults. Participant eligibility will be determined by screening for hemoglobin and ferritin (in combination with C-reactive protein) levels in a sample of venous blood. Eligible individuals will be invited to participate in the study. Enrolled participants will be randomized into one of three intervention groups in a 1:1:1 ratio, receiving either Ferrous Sulfate Capsules, >Your< Iron Forte Capsules, or >Your< Iron Forte Liquid. Efficacy and safety of the assigned interventions will be evaluated through analyses of relevant hematological (hemoglobin, red blood cell indices) and biochemical (ferritin, transferrin saturation) iron-related parameters and reported adverse events after the first 4 and after a total of 12 weeks of intervention.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 152
Est. completion date January 10, 2024
Est. primary completion date January 10, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - Personally signed and dated Informed Consent Form. - Male or female, aged 18-50 years (inclusive) at the time of signing the Informed Consent Form. - Iron deficiency as defined by a hemoglobin value 100-130 g/L (females) and 110-140 g/L (males) and a serum ferritin level <30 µg/L (with C-reactive protein level <10 mg/L). - Generally healthy individual with no known significant health problems as judged by the Investigator (based on the screening questionnaire responses, medical history, the results of clinical laboratory tests performed at screening, and the results of examination of vital signs). - Body mass index =27 kg/m2. - Ability to understand and willingness to comply with all protocol required visits, assessments, and interventions. Exclusion Criteria: - Occult gastrointestinal bleeding (as determined by the fecal occult blood test). - Pronounced symptoms accompanying anemia (i. e., pronounced fatigue, dizziness, shortness of breath). - Hemochromatosis or other iron-loading disorders. - Known hemoglobinopathy (e. g., thalassemia). - Any active or unstable concurrent medical condition (e. g., cancer, renal dysfunction, liver dysfunction). - Presence of an inflammatory and/or autoimmune disorder (e. g., inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, celiac disease). - Partial or total gastrectomy or any other surgical procedure bypassing the duodenum. - Known HIV, HBV, or HCV infection. - Any active chronic or acute infectious disease requiring antibiotic treatment. - Taking regular medication that could affect iron absorption (e. g., antacids, proton pump inhibitors, histamine H2 blockers). - Use of any iron-containing medications or supplements within 30 days prior to screening and at any time throughout the duration of the study. - Received blood transfusion within 12 weeks prior to screening or planned blood transfusion during the study period. - Receipt of i. m. or i. v. injection of depot iron preparation within 30 days prior to screening or at any time during the study. - Receipt of erythropoiesis stimulating agents within 30 days prior to screening or at any time during the study. - Blood donation within the previous 30 days or planned blood donation during the study period. - Scheduled or expected hospitalization and/or surgery during the course of the study. - Intake of concurrent medications that could interfere with physical or mental performance (e. g., antihistamines etc.). - For women of childbearing potential: planning of pregnancy, current pregnancy, or lactation. - Known allergies or severe adverse reactions to previous oral iron therapy or known hypersensitivity to any component of investigational products. - Current participation in any other interventional clinical study or participation within 30 days prior to screening. - Any other unspecified reason (laboratory abnormality, medical condition, or psychiatric or psychological disorder) which, in the opinion of the Investigator, makes the subject unsuitable for participation in the study.

Study Design


Intervention

Dietary Supplement:
Ferrous Sulfate Capsules
Once daily dose of one Ferrous Sulfate Capsule for 12 weeks in total.
>Your< Iron Forte Capsules
Once daily dose of one >Your< Iron Forte Capsule for 12 weeks in total.
>Your< Iron Forte Liquid
Once daily dose of 5 ml of >Your< Iron Forte Liquid for 12 weeks in total.
Other:
Blank Capsules
Once daily dose of one Blank Capsule (excipients only) for 12 weeks in total.
Blank Liquid
Once daily dose of 5 ml of Blank Liquid (excipients only) for 12 weeks in total.

Locations

Country Name City State
Slovenia Diagnostic Laboratory Medicare Plus Ljubljana

Sponsors (1)

Lead Sponsor Collaborator
PharmaLinea Ltd.

Country where clinical trial is conducted

Slovenia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in hemoglobin level from baseline to week 12. Measurement in a venous blood sample. 12 weeks
Secondary Change in hemoglobin from baseline at week 4. Measurement in a venous blood sample. 4 weeks
Secondary Change in hematocrit from baseline at week 4. Measurement in a venous blood sample. 4 weeks
Secondary Change in hematocrit from baseline at week 12. Measurement in a venous blood sample. 12 weeks
Secondary Change in mean corpuscular volume from baseline at week 4. Measurement in a venous blood sample. 4 weeks
Secondary Change in mean corpuscular volume from baseline at week 12. Measurement in a venous blood sample. 12 weeks
Secondary Change in mean corpuscular hemoglobin from baseline at week 4. Measurement in a venous blood sample. 4 weeks
Secondary Change in mean corpuscular hemoglobin from baseline at week 12. Measurement in a venous blood sample. 12 weeks
Secondary Change in mean corpuscular hemoglobin concentration from baseline at week 4. Measurement in a venous blood sample. 4 weeks
Secondary Change in mean corpuscular hemoglobin concentration from baseline at week 12. Measurement in a venous blood sample. 12 weeks
Secondary Change in serum ferritin level from baseline at week 4. Measurement in a venous blood sample. 4 weeks
Secondary Change in serum ferritin level from baseline at week 12. Measurement in a venous blood sample. 12 weeks
Secondary Change in transferrin saturation from baseline at week 4. Measurement in a venous blood sample. 4 weeks
Secondary Change in transferrin saturation from baseline at week 12. Measurement in a venous blood sample. 12 weeks
Secondary Collection and assessment of adverse events. Collection and assessment of adverse events. 4 weeks
Secondary Collection and assessment of adverse events. Collection and assessment of adverse events. 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06027801 - Iron Fortified Food to Improve Japanese Encephalitis and Typhoid Fever Vaccine Immunogenicity N/A
Completed NCT02282553 - Gastric Capsule Examination for Iron Deficiency Anaemia N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Recruiting NCT04913649 - Intravenous Iron to Treat Postoperative Anemia in Older Cardiac Surgery Patients Phase 4
Completed NCT02176759 - Iron Absorption From Rice Fortified With Ferric Pyrophosphate N/A
Completed NCT01438645 - ScopeGuide-assisted Colonoscopy Versus Conventional Colonoscopy N/A
Completed NCT01307007 - Hypophosphatemia With Ferric Carboxymaltose Vs. Iron Dextran in Iron Deficiency Secondary to Heavy Uterine Bleeding Phase 2
Completed NCT00982007 - Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA) Phase 3
Completed NCT00198848 - Iron Supplementation Among Adolescent Girls in India N/A
Completed NCT01166451 - The Anemia Control Program: High or Low Iron Supplementation N/A
Recruiting NCT03893045 - A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects Phase 3
Recruiting NCT03817957 - Postoperative i.v. Iron Substitution in Patients With Diagnosed Iron Deficiency Phase 3
Completed NCT03819530 - Child of Urban Poverty Iron Project (CUPIP) - A Pilot Study N/A
Completed NCT03618914 - Anemia and Inflammation
Completed NCT03940430 - Lactoferrin Versus Ferrous Sulfate in Management of Iron Deficiency Anemia Among Female Medical Ain Shams Students Phase 2/Phase 3
Withdrawn NCT03873584 - Improvement of Fatigue Symptoms in the Iron Deficiency Anemia With Iron Succinylate Therapy
Enrolling by invitation NCT03897673 - Optimizing Benefits While Reducing Risks of Iron in Malaria-endemic Areas N/A
Active, not recruiting NCT04778072 - A Clinical Study on Adherence and Efficacy of Different Doses of Active Iron in Treatment Resistant Subjects N/A
Completed NCT03237065 - Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Phase 3
Completed NCT05153278 - IV Iron Versus Standard Treatment for Iron Deficiency Anemia in the Emergency Department